Article
Genetics & Heredity
Lakshmi Lavanya Reddy, Swarup A. V. Shah, Chandrashekhar K. Ponde, Jamshed J. Dalal, Raj G. Jatale, Reeta J. Dalal, Rajesh M. Rajani, Sudhir K. Pillai, Chander V. Vanjani, Tester F. Ashavaid
Summary: Familial Hypercholesterolemia (FH) is a genetic disorder characterized by high LDL cholesterol levels, with a high risk of Coronary Artery Disease (CAD). A study in India screened the entire PCSK9 gene and hotspot exons of the LDLR gene in FH cases and controls, finding no pathogenic variants in PCSK9 but 3 known pathogenic variants in LDLR. This study contributes to the understanding of the genetic spectrum of FH in India.
JOURNAL OF HUMAN GENETICS
(2021)
Article
Endocrinology & Metabolism
Yiming Wu, Jie Shi, Qing Su, Zhen Yang, Li Qin
Summary: This study found that circulating PCSK9 levels were significantly higher in pregnant women with gestational diabetes mellitus (GDM) compared to those with normal glucose tolerance. The levels of PCSK9 were positively correlated with fasting plasma glucose, glycated hemoglobin, total cholesterol, and low-density lipoprotein cholesterol in the GDM group. Logistic regression analysis showed that age and serum PCSK9 levels were independently associated with GDM. The study suggests a potential link between PCSK9 and GDM.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Alessia Silla, Federica Fogacci, Angela Punzo, Silvana Hrelia, Patrizia Simoni, Cristiana Caliceti, Arrigo F. G. Cicero
Summary: Atherosclerosis and ASCVD can be improved by reducing the levels of LDL cholesterol. A new injectable antibody targeting PCSK9, called Evolocumab, has been approved for better lipid control in high-risk individuals. The use of Evolocumab has shown significant improvement in blood pressure and arterial pulse wave velocity, as well as a decrease in H2O2 production.
Article
Oncology
Emilie Wong Chong, France-Helene Joncas, Nabil G. Seidah, Frederic Calon, Caroline Diorio, Anne Gangloff
Summary: This study aimed to compare the circulating levels of lipid-related factors in women with breast cancer and those with premalignant or benign breast lesions. The results showed that PCSK9 levels were significantly higher in women with breast cancer and positively correlated with disease severity. However, no association was found between ANGPTL3 or Lp(a) levels and breast disease status.
Article
Cardiac & Cardiovascular Systems
Marina Cuchel, Paul C. Lee, Lisa C. Hudgins, P. Barton Duell, Zahid Ahmad, Seth J. Baum, MacRae F. Linton, Sarah D. de Ferranti, Christie M. Ballantyne, John A. Larry, Linda C. Hemphill, Iris Kindt, Samuel S. Gidding, Seth S. Martin, Patrick M. Moriarty, Paul P. Thompson, James A. Underberg, John R. Guyton, Rolf L. Andersen, David J. Whellan, Irwin Benuck, John P. Kane, Kelly Myers, William Howard, David Staszak, Allison Jamison, Mary C. Card, Mafalda Bourbon, Joana R. Chora, Daniel J. Rader, Joshua W. Knowles, Katherine Wilemon, Mary P. McGowan
Summary: This study investigated the diagnosis and treatment of HoFH in the United States and found a low diagnosis rate and low treatment rate, highlighting the need for enhanced screening and treatment to reduce the burden of the disease.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Cardiac & Cardiovascular Systems
Catherine G. Derington, Lisandro D. Colantonio, Jennifer S. Herrick, James Cook, Jordan B. King, Robert S. Rosenson, Bharat Poudel, Keri L. Monda, Ann Marie Navar, Katherine E. Mues, Vanessa W. Stevens, Richard E. Nelson, Megan E. Vanneman, Paul Muntner, Adam P. Bress
Summary: Few adults at high risk for atherosclerotic cardiovascular disease events use a PCSK9i. Factors such as age, family history, and medication use were significantly associated with the initiation of PCSK9i in high-risk patients.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Cardiac & Cardiovascular Systems
Joseph E. Blais, Yue Wei, Kevin K. W. Yap, Hassan Alwafi, Tian-Tian Ma, Ruth Brauer, Wallis C. Y. Lau, Kenneth K. C. Man, Chung Wah Siu, Kathryn C. B. Tan, Ian C. K. Wong, Li Wei, Esther W. Chan
Summary: From 2008 to 2018, global consumption of Lipid-modifying agents, particularly statins, has increased. While the relationship between LMA consumption and cholesterol concentrations remains unclear, the trends in LMA use globally align with international lipid guidelines and show an increase in consumption of low-density lipoprotein lowering therapies. Country-level patterns of LMA use and total and non-HDL cholesterol varied considerably.
Article
Nutrition & Dietetics
Lukas Konecny, Marcel Hrubsa, Jana Karlickova, Alejandro Carazo, Lenka Javorska, Katerina Matousova, Lenka Kujovska Krcmova, Alena Smahelova, Vladimir Blaha, Milan Blaha, Premysl Mladenka
Summary: This study analyzed the antiplatelet effect of 4-MC in FH patients and compared its impact on two FH treatment modalities. The results showed that 4-MC had a stronger inhibitory effect on collagen-induced platelet aggregation in FH patients compared to the healthy control group. The study also found that apheresis improved the inhibitory effect of 4-MC on platelet aggregation, and patients treated with apheresis and pretreated with 4-MC had lower platelet aggregability compared to those solely treated with PCKS9Ab. This study confirmed the suitability of 4-MC as a promising antiplatelet agent and demonstrated its effect in patients with a genetic metabolic disease for the first time.
Article
Cardiac & Cardiovascular Systems
Arihiro Kiyosue, Satoshi Yasuda, Akiyoshi Tomura, Makiko Usami, Hidenori Arai
Summary: This study evaluated the safety and effectiveness of alirocumab in Japanese patients with familial hypercholesterolemia (FH) or non-FH in a real-world clinical setting. The study included treatment naive patients with hypercholesterolemia who had a high risk of developing cardiovascular events. Alirocumab showed effectiveness and was well tolerated in Japanese patients with hypercholesterolemia.
CIRCULATION JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Rodrigo Alonso, Raquel Arroyo-Olivares, Ovidio Muniz-Grijalvo, D. Jose Luis Diaz-Diaz, Juan Sanchez Munoz-Torrero, Manuel J. Romero, Raimundo de Andres, Daniel Zambon, Maria Dolores Manas, Francisco Fuentes-Jimenez, Rocio Aguado, Pilar Alvarez-Banos, Francisco Arrieta, Pablo Gonzalez-Bustos, Jose Cepeda, Mercedes Martin-Ordiales, Daniel Mosquera, Alfredo Michan, Leopoldo Perez de Isla, Rosa Argueso, Pedro Mata
Summary: This study analyzed the persistence, efficacy, and impact on quality of life of PCSK9 inhibitors (PCSK9is) in familial hypercholesterolaemia (FH) patients in clinical practice setting. The results showed that long-term persistence with PCSK9i in FH patients was very high, and it significantly reduced LDL-C levels and achieved treatment goals.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
M. M. Schreuder, S. Hamkour, K. E. Siegers, K. B. Holven, A. K. Johansen, M. A. van de Ree, B. Imholz, E. Boersma, L. Louters, M. P. Bogsrud, K. Retterstol, F. L. J. Visseren, J. E. Roeters van Lennep, C. Koopal
Summary: Only a minority of female and male FH patients achieved their LDL-C treatment target. Women received less high-intensity statins and ezetimibe. The most common reasons for not reaching the target were insufficient effect of medication and side effects.
Article
Medicine, General & Internal
Hayato Tada, Hirofumi Okada, Akihiro Nomura, Soichiro Usui, Kenji Sakata, Kenshi Hayashi, Noboru Fujino, Ayaka Yasugi, Shizuko Takahara, Yasuhito Imai, Masayuki Takamura, Masa-aki Kawashiri
Summary: Familial hypercholesterolaemia (FH) is a genetic disease with elevated cardiovascular risk due to high LDL cholesterol levels. This study aims to compare the effectiveness of AI-supported nutrition therapy with traditional nutrition counseling in FH patients. The study follows ethical guidelines and plans to disseminate results in international conferences and journals.
Article
Cardiac & Cardiovascular Systems
Marc Snel, Olivier S. Descamps
Summary: Anti-PCSK9 mAb is a safe and effective therapeutic option for lowering LDL-C levels in FH patients, allowing a significant portion of patients to reach their lipid targets, especially in those with combined therapy with statins and/or ezetimibe.
Review
Medicine, General & Internal
Jichang Luo, Tianze Huang, Ran Xu, Xue Wang, Yutong Yang, Long Li, Xiao Zhang, Yinhang Zhang, Renjie Yang, Jie Wang, Hai Yang, Yan Ma, Bin Yang, Tao Wang, Liqun Jiao
Summary: This review investigates the impact of commonly available conventional lipid-lowering agents on circulating PCSK9 levels and lipid profiles.
Article
Health Care Sciences & Services
Valentina Perrone, Elisa Giacomini, Diego Sangiorgi, Margherita Andretta, Fausto Bartolini, Alessandro Lupi, Fulvio Ferrante, Stefano Palcic, Davide Re, Luca Degli Esposti
Summary: This study analyzed patient characteristics, lipid profile, therapeutic pathway, and pharmaco-utilization using real-world data in Italy for hypercholesterolemic patients under statin medication. The results highlighted non-optimal therapeutic management and a notable proportion of patients non-adherent to therapy in Italian clinical practice.
RISK MANAGEMENT AND HEALTHCARE POLICY
(2022)
